Last reviewed · How we verify

Diclofenac Capsules high dose — Competitive Intelligence Brief

Diclofenac Capsules high dose (Diclofenac Capsules high dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID. Area: Rheumatology.

phase 2 NSAID COX-2 Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Diclofenac Capsules high dose (Diclofenac Capsules high dose) — Iroko Pharmaceuticals, LLC. Diclofenac works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins, leading to reduced inflammation and pain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Diclofenac Capsules high dose TARGET Diclofenac Capsules high dose Iroko Pharmaceuticals, LLC phase 2 NSAID COX-2
Celebrex celecoxib Pfizer Inc. (originally Searle/Pharmacia) marketed Nonsteroidal Anti-inflammatory Drug [EPC] COX-2 1998-12-31
Cytotec Misoprostol Pfizer marketed NSAID combined with prostaglandin analog Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors 1988-01-01
Diclofenac + Omeprazole Diclofenac + Omeprazole Pfizer's Upjohn has merged with Mylan to form Viatris Inc. marketed NSAID + Proton pump inhibitor combination COX-1/COX-2 (diclofenac); H+/K+-ATPase (omeprazole)
Parestat(generic parecoxib) Parestat(generic parecoxib) University of Malaya marketed Selective COX-2 inhibitor (coxib) COX-2 (Cyclooxygenase-2)
sumatriptan succinate/naproxen sodium sumatriptan succinate/naproxen sodium GlaxoSmithKline marketed 5-HT1B/1D receptor agonist combined with NSAID 5-HT1B receptor, 5-HT1D receptor, COX-1, COX-2
acetaminophen/codeine and ibuprofen acetaminophen/codeine and ibuprofen University of California, Davis marketed Combination analgesic (opioid + NSAID + acetaminophen) Mu opioid receptor (codeine); COX-1/COX-2 (ibuprofen); unclear (acetaminophen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (NSAID class)

  1. Antibe Therapeutics Inc. · 3 drugs in this class
  2. Iroko Pharmaceuticals, LLC · 3 drugs in this class
  3. Organon and Co · 2 drugs in this class
  4. Apsen Farmaceutica S.A. · 2 drugs in this class
  5. Amneal Pharmaceuticals, LLC · 2 drugs in this class
  6. Behar, Caren, M.D. · 2 drugs in this class
  7. IDEA AG · 2 drugs in this class
  8. Noven Pharmaceuticals, Inc. · 2 drugs in this class
  9. HALEON · 2 drugs in this class
  10. Pfizer · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Diclofenac Capsules high dose — Competitive Intelligence Brief. https://druglandscape.com/ci/diclofenac-capsules-high-dose. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: